1. Home
  2. SABS vs CODX Comparison

SABS vs CODX Comparison

Compare SABS & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SABS
  • CODX
  • Stock Information
  • Founded
  • SABS 2014
  • CODX 2013
  • Country
  • SABS United States
  • CODX United States
  • Employees
  • SABS N/A
  • CODX N/A
  • Industry
  • SABS Biotechnology: Pharmaceutical Preparations
  • CODX Medical/Dental Instruments
  • Sector
  • SABS Health Care
  • CODX Health Care
  • Exchange
  • SABS Nasdaq
  • CODX Nasdaq
  • Market Cap
  • SABS 19.0M
  • CODX 22.0M
  • IPO Year
  • SABS N/A
  • CODX 2017
  • Fundamental
  • Price
  • SABS $1.20
  • CODX $0.32
  • Analyst Decision
  • SABS Strong Buy
  • CODX Hold
  • Analyst Count
  • SABS 5
  • CODX 1
  • Target Price
  • SABS $12.40
  • CODX $1.00
  • AVG Volume (30 Days)
  • SABS 36.5K
  • CODX 266.1K
  • Earning Date
  • SABS 05-19-2025
  • CODX 03-27-2025
  • Dividend Yield
  • SABS N/A
  • CODX N/A
  • EPS Growth
  • SABS N/A
  • CODX N/A
  • EPS
  • SABS N/A
  • CODX N/A
  • Revenue
  • SABS $1,512,723.00
  • CODX $3,915,160.00
  • Revenue This Year
  • SABS N/A
  • CODX N/A
  • Revenue Next Year
  • SABS N/A
  • CODX N/A
  • P/E Ratio
  • SABS N/A
  • CODX N/A
  • Revenue Growth
  • SABS N/A
  • CODX N/A
  • 52 Week Low
  • SABS $1.36
  • CODX $0.28
  • 52 Week High
  • SABS $5.01
  • CODX $2.23
  • Technical
  • Relative Strength Index (RSI)
  • SABS 33.63
  • CODX 22.45
  • Support Level
  • SABS $1.53
  • CODX $0.28
  • Resistance Level
  • SABS $1.80
  • CODX $0.50
  • Average True Range (ATR)
  • SABS 0.15
  • CODX 0.06
  • MACD
  • SABS 0.02
  • CODX -0.01
  • Stochastic Oscillator
  • SABS 0.00
  • CODX 11.79

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

About CODX Co-Diagnostics Inc.

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Share on Social Networks: